Corporate Accountability

Trump, Gorsuch, and the Concentration of Economic Power

Details

Monday, March 13, 2017
5:30 pm
Center for American Progress

Throughout his campaign, President Donald Trump railed against concentrated economic power, promising to take on monopolies, banks, and other firms that put their corporate interests ahead of the American people. Yet, Trump has signed executive orders and put forward agency nominees that intend to undo important consumer and regulatory protections and concentrate economic power even further. And in one of his most important first acts as president, Trump nominated conservative Judge Neil Gorsuch to the Supreme Court. A former corporate defense attorney and antitrust expert, Gorsuch, if confirmed, could have a dramatic impact on antitrust law, labor law, and other areas that affect consumers, workers, and the middle class.

On Monday, March 13, the Center for American Progress will explore the concentration of economic power in America, the role that conservative legal philosophy has played in enabling it, and what the Gorsuch nomination means for its future. Sen. Amy Klobuchar (D-MN), a member of the Senate Judiciary Committee and the ranking member of its Subcommittee on Antitrust, Competition Policy, and Consumer Rights, will kick off the event with remarks about the growing concentration of economic power; steps we can take to make antitrust enforcement a more effective tool to address this problem; and the broader economic benefits vigorous enforcement will provide to workers, consumers, and small businesses.

A panel of legal experts will follow with a discussion of the ways the growing wave of concentration—as well as the Trump administration’s changes to the nation’s administrative, civil rights, and other laws—affect the lives of everyday Americans and what the Gorsuch nomination may mean for the future.

Introductory remarks:

  • Winnie Stachelberg, Executive Vice President for External Affairs, Center for American Progress

Opening keynote:

  • Sen. Amy Klobuchar (D-MN)

Featured panelists:

  • Todd A. Cox, Director of Policy, NAACP Legal Defense and Educational Fund, Inc.
  • Deepak Gupta, Founding Partner, Gupta Wessler
  • Jonathan Kanter, Partner, Antitrust Group, Paul, Weiss, Rifkind, Wharton & Garrison LLP
  • Lillian Salerno, former USDA Deputy Undersecretary for Rural Development
  • Elizabeth Wydra, President, Constitutional Accountability Center

Moderator:

  • Sabeel Rahman, Assistant Professor of Law, Brooklyn Law School

More from Corporate Accountability

Corporate Accountability
U.S. Court of Appeals for the Third Circuit

Novartis v. Secretary United States Department of Health and Human Services

In Novartis v. Secretary United States Department of Health and Human Services, the United States Court of Appeals for the Third Circuit is considering whether the Inflation Reduction Act’s Medicare drug price negotiation program is...
Corporate Accountability
January 28, 2025

Federal Deposit Insurance as Jarkesy Waiver

Yale Journal on Regulation
An argument lurking just beneath the surface in a pending Fifth Circuit case could stem...
Corporate Accountability
U.S. Court of Appeals for the Second Circuit

Boehringer Ingelheim v. Department of Health and Human Services

In Boehringer Ingelheim v. Department of Health and Human Services, the United States Court of Appeals for the Second Circuit is considering whether the Inflation Reduction Act’s Medicare drug price negotiation program is an unconstitutional...
Corporate Accountability
U.S. Court of Appeals for the Fifth Circuit

Ortega v. Office of the Comptroller of the Currency

In Ortega v. Office of the Comptroller of the Currency, the United States Court of Appeals for the Fifth Circuit is considering a challenge to the Office of the Comptroller of the Currency’s authority to...
Corporate Accountability
U.S. Court of Appeals for the Fifth Circuit

Burgess v. Whang

In Burgess v. Whang, the Fifth Circuit is considering a challenge to the Federal Deposit Insurance Corporation’s authority to issue penalties and other supervisory orders. 
Corporate Accountability
October 23, 2024

The Constitution Doesn’t Entitle Drug Manufacturers to a Sweetheart Deal

Washington
Big Pharma is in federal appeals court making the absurd argument that Medicare shouldn’t be...
By: Nina Henry